Skip to main content
main-content
Top

14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Expert commentary: Fenebrutinib in RA

share
SHARE
print
PRINT
insite
SEARCH

Roy Fleischmann gives his thoughts on the phase IIb fenebrutinib findings in patients with biologic DMARD-refractory rheumatoid arthritis (1:09).

​​​​​​​

share
SHARE
print
PRINT

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?